22
May
2014
|
00:00
Europe/Amsterdam

Complex Lesion BIOFLOW-III Subgroup Analyses Further Support Top Performance of BIOTRONIK Orsiro

Industry’s First Hybrid Drug-Eluting Stent Shown to be Effective in Patients with B2/C Lesions

BUELACH, Switzerland, May 22, 2014 – BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced new results from the subgroup analyses of the BIOFLOW-III registry at this year’s EuroPCR congress in Paris, France. The results were presented by investigator Dr. Jan van der Heijden, St. Antonius Hospital, Nieuwegein, Netherlands, and confirm earlier excellent safety and efficacy results for Orsiro.

BIOFLOW-III is an open-label clinical evaluation of Orsiro with Target Lesion Failure (TLF) rate at 12 months as the primary endpoint, enrolling 1,356 patients at 43 sites in 14 countries. Pre-specified sub-groups were diabetes, small vessel (≤2.75 mm), chronic total occlusion (CTO), and acute myocardial infarction (AMI). 743 subjects (55 percent) presented B2 or C type lesions, classified in accordance with ACC/AHA guidelines.

Preliminary data for this complex population demonstrated excellent device and procedure success (99.3 and 98.2 percent, respectively). Clinical data showed a low TLF rate of 5.1 percent and a definite and probable stent thrombosis rate of 0.5 percent up to the 12-month follow-up. This subgroup analysis demonstrated that the clinical performance of Orsiro is comparable to the overall cohort. “We are excited to have proven the excellent efficacy of the Orsiro stent in a complex patient population,” commented Dr. van der Heijden.

“At BIOTRONIK we are committed to enhancing physicians’ clinical effectiveness and ensuring the highest quality of medical procedures. Our unique coronary stent portfolio, featuring the Masterpieces Orsiro, PRO-Kinetic Energy, and PK Papyrus, represents a prominent example of our ambitions," commented Dr. Daniel Bühler, President BIOTRONIK Vascular Intervention.

    About BIOTRONIK:

    BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.